Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.51 |
| ▸ | THRB | P10828 | 3/20 | 0.51 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16296983 | 0.90 | TGFBR1 (0.53) | TGFBR1MAPK14THRBTGFBR2HRH3 | |
| SCHEMBL29832378 | 0.89 | TGFBR1 (0.53) | TGFBR1MAPK14THRBTGFBR2 | |
| SCHEMBL4865494 | 0.89 | TGFBR1 (0.53) | TGFBR1MAPK14THRBTGFBR2 | |
| SCHEMBL409552 | 0.88 | TGFBR1 (0.53) | TGFBR1MAPK14THRBTGFBR2 | |
| SCHEMBL4864349 | 0.88 | TGFBR1 (0.65) | TGFBR1MAPK14THRBTGFBR2 | |
| SCHEMBL4871888 | 0.86 | TGFBR1 (0.55) | TGFBR1MAPK14THRBTGFBR2 | |
| SCHEMBL4863433 | 0.86 | TGFBR1 (0.58) | TGFBR1MAPK14THRBTGFBR2 | |
| SCHEMBL4868918 | 0.85 | TGFBR1 (0.50) | TGFBR1MAPK14THRBTGFBR2 | |
| SCHEMBL414708 | 0.85 | TGFBR1 (0.57) | TGFBR1MAPK14THRBTGFBR2 | |
| SCHEMBL412950 | 0.84 | TGFBR1 (0.54) | TGFBR1MAPK14THRBTGFBR2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365066-B2 | Pyrazolopyridine derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-04-29 | — | — | US | claimed |
| EP-1543001-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | claimed |
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | BEIGHT DOUGLAS W | 2005-10-06 | — | — | US | claimed |
| EP-1543001-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2005-06-22 | — | — | EP | claimed |
| WO-2004026871-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | claimed |
| US-20160115447-A1 | COMPOSITIONS AND METHODS FOR IMPROVING INDUCED NEURON GENERATION | HOWARD HUGHES MEDICAL INSTITUTE | 2016-04-28 | — | — | US | disclosed |
| US-20140120621-A1 | TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-8603818-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-8298825-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120021519-A1 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| US-7365066-B2 | Pyrazolopyridine derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1543001-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | BEIGHT DOUGLAS W | 2005-10-06 | — | — | US | disclosed |
| EP-1543001-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004026871-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | TGFB2, TGFB1, TGFBR1 | TGFBR1 3/4885MAPK14 106/4885THRB 176/4885 |
| US-20160115447-A1 | COMPOSITIONS AND METHODS FOR IMPROVING INDUCED NEURON GENERATION | PLK1, GAP43, NEFM | TGFBR1 2217/4885MAPK14 421/4885THRB 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.